- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1057EUR$1,200USD£929GBP
€1321EUR$1,500USD£1,161GBP
- Report
- November 2025
- 200 Pages
Global
From €5602EUR$6,360USD£4,924GBP
€7002EUR$7,950USD£6,155GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1409EUR$1,600USD£1,239GBP
€1762EUR$2,000USD£1,548GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1762EUR$2,000USD£1,548GBP
€2202EUR$2,500USD£1,935GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1057EUR$1,200USD£929GBP
€1321EUR$1,500USD£1,161GBP
- Report
- December 2025
- 179 Pages
Global
From €5152EUR$5,850USD£4,529GBP
- Report
- August 2024
- 82 Pages
Japan
From €3083EUR$3,500USD£2,710GBP
Interleukin 13 (IL-13) is a cytokine that plays a role in the regulation of the immune system. It is involved in the development of immune disorders such as asthma, allergies, and inflammatory bowel disease. IL-13 is a key target for drug development in the immune disorders market, as it has been shown to reduce inflammation and improve symptoms.
IL-13 is a promising target for drug development due to its ability to modulate the immune system. It has been shown to reduce inflammation and improve symptoms in a variety of immune disorders. Additionally, IL-13 has been shown to be effective in combination with other drugs, making it a viable option for combination therapies.
Several companies are developing drugs targeting IL-13 for the treatment of immune disorders. These include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more